

Leqembi (lecanemab-irmb)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the gradual decline of cognitive functions, including memory, thinking, and reasoning abilities. It is the most common cause of dementia in older adults, affecting millions of people worldwide. While the majority of cases occur in individuals over 65 years of age, early-onset Alzheimer's can develop in people as young as 40.

The exact cause of Alzheimer's disease is not fully understood, but it is believed to result from a combination of genetic, environmental, and lifestyle factors. At the microscopic level, the disease is associated with the accumulation of amyloid-beta (A β) plaques and neurofibrillary tangles in the brain, which contribute to neuronal dysfunction and cell death.

Currently, there is no cure for Alzheimer's disease. Treatment focuses on managing symptoms, slowing disease progression, and improving the quality of life for patients and their caregivers. Available treatments can be categorized into symptomatic treatments, disease-modifying therapies, and non-pharmacological interventions:

- Symptomatic treatments: These medications aim to alleviate cognitive and behavioral symptoms, such as memory loss and confusion. Commonly used drugs include cholinesterase inhibitors (e.g., donepezil, rivastigmine, and galantamine) and the NMDA receptor antagonist memantine. While these treatments can help manage symptoms, they do not address the underlying disease progression.
- Disease-modifying therapies: Disease-modifying therapies target the underlying pathophysiology of Alzheimer's disease, with the goal of slowing or halting its progression. Two notable examples of these therapies include Leqembi (lecanemab-irmb) and Kisunla (donanemab-azbt), both of which are amyloid beta-directed antibodies designed to reduce amyloid plaque accumulation in the brain.
- Non-pharmacological interventions: A comprehensive approach to Alzheimer's disease management includes non-pharmacological strategies, such as cognitive stimulation, physical activity, and social engagement. These interventions play a critical role in preserving cognitive function, delaying symptom progression, and improving overall quality of life. Caregiver support and education are also essential components of patient care.

Leqembi (lecanemab-irmb) is a monoclonal antibody that specifically targets aggregated forms of amyloid-beta, promoting their clearance from the brain. It is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stages, consistent with the populations studied in clinical trials. There are no safety or efficacy data to support initiating treatment at earlier or later stages of the disease than those studied.

Definitions

"ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive Subscale)" is a widely used cognitive test specifically designed to evaluate the cognitive function of individuals with Alzheimer's disease. It assesses various cognitive domains, such as memory, language, praxis, and orientation. The ADAS-Cog has multiple versions with different numbers of items; the 14-item version is often used in clinical trials. Higher scores on the ADAS-Cog indicate greater cognitive impairment.

"ADCOMS (Alzheimer's Disease Composite Score)" is a composite score that combines selected items from the CDR-SB, MMSE, and ADAS-Cog to create a single measure of cognitive and functional

performance in Alzheimer's disease. The ADCOMS has been developed specifically for use in clinical trials to detect treatment effects in the early stages of the disease.

"Alzheimer's disease (AD)" is a progressive neurodegenerative disorder characterized by a decline in cognitive functions, such as memory, thinking, and reasoning abilities. It is the most common cause of dementia in older adults.

"Amyloid-beta (A β) plaques" are abnormal protein deposits that accumulate in the brain and are associated with Alzheimer's disease. They consist of amyloid-beta peptides, which are thought to contribute to neuronal dysfunction and cell death.

"CDR-SB (Clinical Dementia Rating Scale Sum of Boxes)" is a widely used tool to assess the severity of dementia, particularly Alzheimer's disease. It measures cognitive and functional performance in six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a scale from 0 (no impairment) to 3 (severe impairment), resulting in a sum of boxes score ranging from 0 to 18, with higher scores indicating greater severity of dementia.

"Cholinesterase inhibitors" is a class of drugs used to treat Alzheimer's disease by increasing the levels of the neurotransmitter acetylcholine in the brain, which can help improve cognitive function. Examples include donepezil, rivastigmine, and galantamine.

"Dementia" is a general term for a decline in mental ability severe enough to interfere with daily life. It is not a specific disease but an overall term that describes a wide range of symptoms associated with a decline in memory or other thinking skills.

"Disease-modifying therapies" refer to treatments that aim to target the underlying pathophysiology of a disease, with the goal of slowing down or halting its progression.

"Experimental or Investigational" are terms used to describe treatments, procedures, or services that are not considered standard of care or have not been proven to be safe and effective for a specific condition. These treatments are generally not covered by the Plan.

"MMSE (Mini-Mental State Examination)" is a brief, 30-point questionnaire that is used to assess cognitive function in older adults. It measures various cognitive domains, including orientation,

registration, attention and calculation, recall, and language. The MMSE is scored from 0 to 30, with lower scores indicating more severe cognitive impairment.

“Neurofibrillary tangles” are abnormal accumulations of the protein tau inside brain cells that are also associated with Alzheimer's disease. These tangles disrupt the normal functioning of cells and are thought to contribute to cell death.

“NMDA receptor antagonist” is a type of drug that blocks the NMDA receptor, a protein involved in the communication between brain cells. Memantine is an NMDA receptor antagonist used to treat Alzheimer's disease.

“PET SUVR (Positron Emission Tomography Standardized Uptake Value Ratio)” is a quantitative measure used in amyloid PET imaging to assess the levels of amyloid-beta plaques in the brain. In the context of Alzheimer's disease, PET SUVR is used to determine the extent of amyloid-beta plaque accumulation in specific brain regions. Higher SUVR values indicate higher levels of amyloid-beta plaques, which are associated with Alzheimer's disease.

“Symptomatic treatments” refers to medications that aim to alleviate the cognitive and behavioral symptoms of a disease, such as memory loss and confusion, without addressing the underlying disease progression.

Policy Statement on Leqembi (lecanemab-irmb) for Alzheimer's Disease Efficacy Information

The use of Leqembi (lecanemab-irmb) is considered not medically necessary for the treatment of Alzheimer's disease or any other indication, as the available evidence is insufficient to demonstrate clinically meaningful benefit that outweighs potential risks.

- The CLARITY AD trial demonstrated a 27% slowing of cognitive decline, as measured by the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), with a mean difference of -0.45 points between lecanemab and placebo over 18 months. Secondary outcomes, including changes in ADAS-Cog14 and ADCS-MCI-ADL, also favored lecanemab over placebo.
 - Lecanemab reduced amyloid-beta plaque burden significantly, with a mean reduction of -55.48 centiloids compared to +3.64 centiloids for placebo.
- While the reduction in cognitive decline is statistically significant, the clinical meaningfulness of the modest benefit (-0.45 on CDR-SB) remains debated, particularly when weighed against the progressive nature of Alzheimer's disease.

- Long-term outcomes, such as the impact on quality of life, caregiver burden, and overall disease progression, remain unclear.
- Safety Considerations
 - Amyloid-Related Imaging Abnormalities (ARIA) was observed in 21% of patients in the CLARITY AD trial, with symptomatic ARIA occurring in 3% of patients. Serious adverse events, including intracerebral hemorrhage, were reported in 0.7% of patients.
 - Risk of ARIA is significantly higher in ApoE ε4 homozygotes, with 45% of homozygotes experiencing ARIA compared to 19% of heterozygotes and 13% of noncarriers.
 - Infusion-related reactions were reported in 26% of patients, with most occurring during the first infusion. Symptoms included fever, chills, nausea, and hypotension.
 - Fatal intracerebral hemorrhage events have been reported in a small number of patients, particularly those on anticoagulants or with risk factors for cerebral amyloid angiopathy.
- Lecanemab requires intensive safety monitoring, including baseline and periodic MRIs to detect ARIA, which may limit its feasibility in routine clinical practice.

Medical Necessity Criteria for Leqembi (lecanemab-irmb) for Alzheimer's Disease

Leqembi (lecanemab-irmb) is considered not medically necessary for any indication, including for the treatment of Alzheimer's disease.

Experimental or Investigational / Not Medically Necessary

Leqembi (lecanemab-irmb) is considered experimental, investigational, and not medically necessary for the following indications:

- the treatment of Alzheimer's disease, including:
 - mild cognitive impairment or mild dementia stage of the disease.
 - moderate to severe Alzheimer's disease or other stages of dementia.
- Treatment of other neurodegenerative disorders or cognitive impairments unrelated to Alzheimer's disease.
- Prophylactic or preventive treatment in individuals without Alzheimer's disease or at risk for developing Alzheimer's disease.
- Use in combination with other experimental or investigational therapies for Alzheimer's disease or other cognitive disorders.

While clinical trials have demonstrated some potential for slowing cognitive decline in patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, the overall clinical utility of Leqembi (lecanemab-irmb) remains uncertain. This determination is based on the following key factors:

1. The CLARITY AD trial demonstrated a statistically significant reduction in cognitive decline, with a 27% slowing of progression as measured by the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB). However, the absolute difference in CDR-SB scores between lecanemab and placebo (-0.45 points) is modest and of uncertain clinical significance, particularly when weighed against the progressive nature of Alzheimer's disease and the limited impact on functional outcomes.
2. Leqembi (lecanemab-irmb) is associated with amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema) and ARIA-H (hemorrhage), which occurred in 21% of patients treated with lecanemab in the CLARITY AD trial. Symptomatic ARIA occurred in 3% of patients, and serious adverse events, including intracerebral hemorrhage, were reported in 0.7% of patients. These risks are particularly pronounced in ApoE ϵ 4 homozygotes, who represent a significant subset of the Alzheimer's population.
3. Treatment with Leqembi (lecanemab-irmb) requires frequent and rigorous safety monitoring, including baseline and periodic MRIs to detect ARIA. This level of monitoring may not be feasible in routine clinical practice and adds to the overall burden of care for patients and caregivers.
4. While the CLARITY AD trial provides short-term data on efficacy and safety, there is insufficient evidence to demonstrate the long-term benefits of Leqembi (lecanemab-irmb), including its ability to meaningfully alter the course of Alzheimer's disease or improve quality of life. Real-world effectiveness data are also lacking.
5. While Leqembi (lecanemab-irmb) has received FDA traditional approval, professional guidelines have not yet broadly endorsed its routine use. The Alzheimer's Disease and Related Disorders Therapeutics Work Group has issued appropriate use recommendations, but broader consensus on its role in clinical practice is still evolving.

The Plan will continue to monitor emerging evidence, including long-term data from ongoing clinical trials, real-world evidence from the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), and updated guidance from professional organizations. Until such evidence is available, healthcare providers and members are encouraged to explore alternative treatment options with established efficacy and safety profiles.

Applicable Billing Codes (HCPCS/CPT Codes)

CPT/HCPCS Codes considered experimental or investigational or not considered medically necessary:	
<i>Code</i>	<i>Description</i>
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
J0174	Injection, lecanemab-irmb, 1mg
ICD-10 Codes considered experimental or investigational or not considered medically necessary:	
<i>Code</i>	<i>Description</i>
G30	Alzheimer's disease
G30.0	Alzheimer's disease with early onset
G30.1	Alzheimer's disease with late onset
G30.8	Other Alzheimer's disease
G30.9	Alzheimer's disease, unspecified
G31.84	mild cognitive impairment
F00	Dementia in Alzheimer's disease
F00.0	Dementia in Alzheimer's disease with early onset
F00.1	Dementia in Alzheimer's disease with late onset
F00.2	Dementia in Alzheimer's disease, atypical or mixed type
F00.9	Dementia in Alzheimer's disease, unspecified
F01	Vascular dementia
F01.50	Vascular dementia without behavioral disturbance
F01.51	Vascular dementia with behavioral disturbance
F02	Dementia in other diseases classified elsewhere
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance

F03	Unspecified dementia
F03.90	Unspecified dementia without behavioral disturbance
F03.91	Unspecified dementia with behavioral disturbance
F05	Delirium due to known physiological condition

References

1. Alzheimer's Association. (2023). Alzheimer's disease facts and figures. Retrieved March 17, 2023, from <https://www.alz.org/alzheimers-dementia/facts-figures>
2. Arroyo-Pacheco N, Sarmiento-Blanco S, Vergara-Cadavid G, Castro-Leones M, Contreras-Puentes N. Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis. *Ageing Res Rev.* 2024 Dec 3;104:102620. doi: 10.1016/j.arr.2024.102620. Epub ahead of print. PMID: 39638097.
3. Bloom, G. S. (2014). Amyloid- β and tau: the trigger and bullet in Alzheimer disease pathogenesis. *JAMA Neurol,* 71(4), 505-508. <https://doi.org/10.1001/jamaneurol.2013.5847>
4. Burke JF, Kerber KA, Langa KM, Albin RL, Kotagal V. Lecanemab: Looking Before We Leap. *Neurology.* 2023 Oct 10;101(15):661-665. doi: 10.1212/WNL.0000000000207505. Epub 2023 Jul 21. Erratum in: *Neurology.* 2023 Oct 17;101(16):730. doi: 10.1212/WNL.0000000000207914. PMID: 37479527; PMCID: PMC10585683.
5. Centers for Medicare & Medicaid Services. (2022, April 7). Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease. National Coverage Analysis Decision Memo. Retrieved March 17, 2023, from <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=305>
6. Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S. Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimers Dis.* 2023;10(3):362-377. doi: 10.14283/jpad.2023.30. PMID: 37357276; PMCID: PMC10313141.
7. Dhadda, S., et al. (2022). Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease. *Alzheimer's Research & Therapy,* 14(1), 182. <https://doi.org/10.1186/s13195-022-01129-x>
8. Eli Lilly. (2022, November 30). Lilly shares positive donanemab data in first active comparator study in early symptomatic Alzheimer's disease. News release. Retrieved March 17, 2023, from <https://investor.lilly.com/news-releases/news-release-details/lilly-shares-positive-donanemab-data-first-active-comparator>
9. Knopman DS, Hershey L. Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift? *Neurology.* 2023 Oct 3;101(14):610-620. doi: 10.1212/WNL.0000000000207438. Epub 2023 Jun 9. PMID: 37295957; PMCID: PMC10573150.
10. Leqembi (lecanemab) [prescribing information]. Nutley, NJ: Eisai Inc; January 2023.
11. Leqembi (lecanemab) [prescribing information]. Nutley, NJ: Eisai Inc; November 2024.
12. Li, Y., et al. (2022). Validation of Plasma Amyloid- β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. *Neurology,* 98(7), e688-e699. <https://doi.org/10.1212/WNL.0000000000013211>

13. Logovinsky, V., Satlin, A., Lai, R., et al. (2016). Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective A β antibody. *Alzheimers Res Ther*, 8(1), 14. <https://doi.org/10.1186/s13195-016-0181-2>
14. McDade, E., Cummings, J. L., Dhadda, S., et al. (2022). Lecanemab in patients with early Alzheimer's disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. *Alzheimers Res Ther*, 14(1), 191. <https://doi.org/10.1186/s13195-022-01124-2>
15. McDade, E., et al. (2022). Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. *Alzheimer's Research & Therapy*, 14(1), 191. <https://doi.org/10.1186/s13195-022-01124-2>
16. Park J, Simpson C, Patel K. Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease. *Ann Pharmacother*. 2024 Oct;58(10):1045-1053. doi: 10.1177/10600280231218253. Epub 2023 Dec 14. PMID: 38095619.
17. Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. *Front Aging Neurosci*. 2023 May 5;15:1169499. doi: 10.3389/fnagi.2023.1169499. PMID: 37213538; PMCID: PMC10196238.
18. Ramanan VK, Armstrong MJ, Choudhury P, Coerver KA, Hamilton RH, Klein BC, Wolk DA, Wessels SR, Jones LK Jr; AAN Quality Committee. Anti-amyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology. *Neurology*. 2023 Nov 7;101(19):842-852. doi: 10.1212/WNL.0000000000207757. Epub 2023 Jul 26. PMID: 37495380; PMCID: PMC10663011.
19. Satlin, A., et al. (2016). Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 2(1), 1-12. <https://doi.org/10.1016/j.trci.2016.01.001>
20. Sun, X., Chen, W. D., & Wang, Y. D. (2015). β -Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. *Front Pharmacol*, 6, 221. <https://doi.org/10.3389/fphar.2015.00221>
21. Swanson, C. J., et al. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody [published correction appears in *Alzheimer's Research & Therapy*. 2022 May 21;14(1):70]. *Alzheimer's Research & Therapy*, 13(1), 80. <https://doi.org/10.1186/s13195-021-00813-8>
22. Swanson, C. J., Zhang, Y., Dhadda, S., et al. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody [published correction appears in *Alzheimers Res Ther*. May 21, 2022;14(1):70]. *Alzheimers Res Ther*, 13(1), 80. <https://doi.org/10.1186/s13195-021-00813-8>
23. Tahami Monfared, A. A., Tafazzoli, A., Ye, W., Chavan, A., & Zhang, Q. (2022). Long-term health outcomes of lecanemab in patients with early Alzheimer's disease using simulation modeling. *Neurol Ther*, 11(2), 863-880. <https://doi.org/10.1007/s40120-022-00350-y>
24. Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020). Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. *Alzheimers Res Ther*, 12(1), 95. <https://doi.org/10.1186/s13195-020-00663-w>
25. U.S. House of Representatives Committee on Oversight and Reform and Committee on Energy and Commerce. (2022, December). The High Price of Aduhelm's Approval: An Investigation into FDA's Atypical Review Process and Biogen's Aggressive Launch Plans. Staff Report. Retrieved March 17, 2023, from

<https://oversightdemocrats.house.gov/sites/democrats.oversight.house.gov/files/2022-12-29.COR%20%26%20E%26C%20Joint%20Staff%20Report%20re.%20Aduhelm.pdf>

26. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. PMID: 36449413.

Clinical Guideline Revision / History Information

Original Date: 4/24/2023

Reviewed/Revised: 7/31/2023, 10/27/2023, 12/19/2024